OncoMatch/Clinical Trials/NCT06959641
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Is NCT06959641 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Zanzalintinib for locally advanced differentiated thyroid gland carcinoma.
Treatment: Zanzalintinib — This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). XL092 is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IV, STAGE III, STAGE IV (AJCC v8)
locally advanced or metastatic, radioactive iodine (RAI) refractory, differentiated thyroid cancer...measurable disease according to RECIST v 1.1
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: XL092 (zanzalintinib) (XL092)
Prior treatment with XL092 (zanzalintinib)
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor treatment (including investigational kinase inhibitor) within 2 weeks before the first dose of study treatment
Cannot have received: cytotoxic, biologic, or other systemic anticancer therapy
Exception: nitrosoureas or mitomycin C < 6 weeks prior to planned treatment start date
Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational therapy or investigational device) within 4 weeks before the first dose of study treatment
Cannot have received: radiation therapy for bone metastases
Radiation therapy for bone metastases within 2 weeks before the first dose of study treatment
Cannot have received: other radiation therapy
any other radiation therapy within 4 weeks before the first dose of study treatment
Cannot have received: systemic treatment with radionuclides
Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment
Lab requirements
Blood counts
Leukocytes (WBC) ≥ 3,000/mcL; ANC ≥ 1,500/mcL; Hemoglobin ≥ 9 g/dL; Platelets ≥ 100,000/mcL
Kidney function
Creatinine Clearance (CrCl) ≥ 40 mL/min (≥ 0.67 mL/sec) using Cockcroft-Gault equation
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's disease); AST ≤ 3 x ULN; ALT ≤ 3 x ULN; ALP ≤ 3 x ULN (≤ 5 x ULN for bone metastasis)
Cardiac function
QTcF ≤ 480 ms within 14 days per ECG before first dose
Leukocytes (WBC) ≥ 3,000/mcL; ANC ≥ 1,500/mcL; Hemoglobin (Hgb) ≥ 9 g/dL; Platelets (PLT) ≥ 100,000/mcL; Total bilirubin ≤ 1.5 x ULN; AST ≤ 3 x ULN; ALT ≤ 3 x ULN; ALP ≤ 3 x ULN; CrCl ≥ 40 mL/min; QTcF ≤ 480 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwestern University · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify